Who Exports Thalidomide from India — 153 Suppliers Behind a $1.9M Market
India's thalidomide export market is supplied by 153 active exporters who collectively shipped $1.9M across 822 shipments. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED leads with a 24.2% market share, followed by UNITED BIOTECH PRIVATE LIMITED and JODAS EXPOIM PRIVATE LIMITED. The top 5 suppliers together control 65.9% of total export value, reflecting a concentrated market structure.
Top Thalidomide Exporters from India — Ranked by Export Value
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED is the leading thalidomide exporter from India, holding a 24.2% share of the $1.9M market across 822 shipments from 153 exporters. The top 5 suppliers — BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED, UNITED BIOTECH PRIVATE LIMITED, JODAS EXPOIM PRIVATE LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, KANCHAN SAGAR PHARMACEUTICALS — collectively control 65.9% of total export value, indicating a moderately concentrated market. Individual shares are: BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED (24.2%), UNITED BIOTECH PRIVATE LIMITED (15.9%), JODAS EXPOIM PRIVATE LIMITED (13.3%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (7.4%), KANCHAN SAGAR PHARMACEUTICALS (5.1%).
Top Thalidomide Exporters from India
Ranked by export value · 153 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED THALIDOMIDE CAPSULES USP 100MG (BDOMIDETHALIDOMIDE 100 MG CAPSULESTHALIDOMIDE 100 MG GLES | $468.6K | 2 | 24.2% |
| 2 | UNITED BIOTECH PRIVATE LIMITED THALIDE 100 CAPSULE THALIDOMIDE CAPSULESTHALIDE 50 CAPSULE THALIDOMIDE CAPSULESTHALIDE 50,THALIDOMIDE CAPSULES USP 50MG | $307.7K | 4 | 15.9% |
| 3 | JODAS EXPOIM PRIVATE LIMITED THALIDOMIDE CAPSULES USP 100MGTHALIDOMIDE CAPSULES USP 100MG NOSTHALIDOMIDE CAPSULES USP 50MG | $257.8K | 1 | 13.3% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED THALIDOMIDE CAPSULES USP 100MG (BDOMIDETHALOMA CAP 100MGTHALIDOMIDE 100 MG CAPSULES | $142.5K | 2 | 7.4% |
| 5 | KANCHAN SAGAR PHARMACEUTICALS THALOMA CAP 100MGTHALIDSP 100 (THALIDOMIDE CAPS USP 100 M | $98.7K | 1 | 5.1% |
| 6 | HETERO LABS LIMITED THALDEX 100MG THALIDOMIDE 100 MG CAPS BATHALDEX THALIDOMIDE CAPSULE 10S | $86.6K | 4 | 4.5% |
| 7 | ACCURE LABS PRIVATE LIMITED THALIDOMIDE CAPSULES USP 100MGTHALIDOMIDE CAPSULES USP 100MG NOSTHALOMA CAP 100MG | $74.5K | 1 | 3.9% |
| 8 | 3S PHARMACEUTICALS INDIA PRIVATE LIMITED THALIDOMIDE CAPSULES 100 MG USPTHALIDOMIDE CAPSULES USP 100 MG 1*10 STRTHALIDOMIDE 50MG CAPSULE, BRAND : THALIX | $34.7K | 5 | 1.8% |
| 9 | GLOBELA PHARMA PRIVATE LIMITED | $23.0K | 4 | 1.2% |
| 10 | VAMA LIFECARE PRIVATE LIMITED TAB.THALIPRIN 100MGTHALIDOMIDE | $17.6K | 6 | 0.9% |
| 11 | DR GOYAL MEDICAL PRIVATE LIMITED THALIDOMIDE CAPSULES USP 100MG (BDOMIDETHALIDOMIDE 100 MG CAPSULESTHALIDOMIDE 100 MG GLES | $16.1K | 2 | 0.8% |
| 12 | DOSHI MEDICARE PRIVATE LIMITED | $15.2K | 6 | 0.8% |
| 13 | RIZLIFE HEALTHCARE THALINEW 100 MG THALIDOMIDE CAPSULE 100MTHALIX 100 BTTHALIX 50 BT N | $14.8K | 3 | 0.8% |
| 14 | AVALOR HEALTH CARE PRIVATE LIMITED | $14.7K | 1 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Thalidomide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter, December | Yes, as of 2015 | Yes | Not verified | Received FDA warning letter in 2015 for CGMP violations at Halol facility. |
| Hetero Labs Limited | Warning Letter, March 202 | Yes, as of 2025 | Yes | Not verified | Received FDA warning letter in 2025 for CGMP violations at Hyderabad facility. |
| BDR Pharmaceuticals International Private Limited | Not Listed | Yes, as of 2024 | Yes | Not verified | Holds WHO-GMP and EU GMP certifications as of 2024. |
| Jodas Expoim Private Limited | Not Listed | Yes, as of 2023 | Yes | Not verified | Holds WHO-GMP and EU GMP certifications as of 2023. |
| United Biotech Private Limited | Not Listed | Yes, as of 2022 | Yes | Not verified | Holds WHO-GMP and EU GMP certifications as of 2022. |
| Kanchan Sagar Pharmaceuticals | Not Listed | Yes, as of 2023 | Yes | Not verified | Holds WHO-GMP and EU GMP certifications as of 2023. |
| Accure Labs Private Limited | Not Listed | Yes, as of 2024 | Yes | Not verified | Holds WHO-GMP and EU GMP certifications as of 2024. |
| 3S Pharmaceuticals India Private Limited | Not Listed | Yes, as of 2023 | Yes | Not verified | Holds WHO-GMP and EU GMP certifications as of 2023. |
TransData Nexus reviewed the regulatory standing of 8 leading Thalidomide exporters from India. 0 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Thalidomide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's "Bulk Drug Capital," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical landscape is anchored by Genome Valley, a hub for R&D and biologics, and Hyderabad Pharma City, an emerging integrated cluster aimed at consolidating APIs, formulations, and support services. This robust infrastructure positions Hyderabad as a pivotal player in the production of APIs like Thalidomide.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant hub for pharmaceutical formulations. This region hosts major companies such as Torrent Pharmaceuticals, Zydus Cadila Healthcare, and Intas Pharmaceuticals, all of which have substantial manufacturing facilities. The presence of these industry leaders underscores the region's capacity for producing finished pharmaceutical products, including Thalidomide formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. Mumbai, being the headquarters of Sun Pharmaceutical Industries Limited, the largest pharmaceutical company in India, plays a central role in the export of pharmaceuticals. The region's well-established logistics and port facilities facilitate the efficient export of drugs like Thalidomide to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 3,120 factories with an annual turnover of ₹60,000 crore. The region's industrial growth has been significantly influenced by tax incentives, attracting numerous pharmaceutical companies. However, the expiration of these tax holidays necessitates a reassessment of cost structures for continued competitiveness.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 65.9% of Thalidomide exports, it's prudent to diversify the supplier base to mitigate risks associated with over-reliance on a few sources.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers in Hyderabad and Ahmedabad-Vadodara clusters to ensure consistent quality and supply.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline logistics and reduce lead times for international shipments.
- Monitor Regulatory Changes: Stay informed about policy shifts, especially concerning tax incentives in regions like Baddi-Nalagarh, to anticipate and adapt to potential cost implications.
By strategically engaging with these pharmaceutical clusters and adhering to these recommendations, TransData Nexus can optimize its Thalidomide sourcing strategy, ensuring a resilient and efficient supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Thalidomide exporters from India
BDR Pharmaceuticals International Private Limited — BDR Pharmaceuticals plans $100 million US manufacturing expansion
BDR Pharmaceuticals announced plans to invest $100 million in acquiring manufacturing facilities in the United States to enhance its presence in the US market. The company is evaluating potential units and expects to finalize acquisitions within three to four months, funding the expansion through internal accruals. - IMPACT: This expansion may bolster BDR's production capabilities, potentially increasing Thalidomide exports.
Impact: This expansion may bolster BDR's production capabilities, potentially increasing Thalidomide exports.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma acquired Checkpoint Therapeutics, a US-based immunotherapy and targeted oncology company, for $355 million. This acquisition includes UNLOXCYT (cosibelimab), an FDA-approved anti-PD-L1 treatment for skin cancer, enhancing Sun Pharma's oncology portfolio and US market presence. (pedb.uk) - IMPACT: The acquisition strengthens Sun Pharma's oncology offerings, which may indirectly influence Thalidomide export strategies.
Impact: The acquisition strengthens Sun Pharma's oncology offerings, which may indirectly influence Thalidomide export strategies.
Sun Pharmaceutical Industries Limited — Sun Pharma completes merger with Taro Pharmaceuticals
Sun Pharma completed its merger with Taro Pharmaceuticals, consolidating their operations to enhance market reach and operational efficiencies. - IMPACT: The merger may lead to streamlined operations, potentially affecting Thalidomide production and export dynamics.
Impact: The merger may lead to streamlined operations, potentially affecting Thalidomide production and export dynamics.
Common Questions — Thalidomide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which thalidomide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED leads with 23 recorded shipments worth $468.6K. UNITED BIOTECH PRIVATE LIMITED (18 shipments) and JODAS EXPOIM PRIVATE LIMITED (12 shipments) are also established high-volume exporters.
Q How many thalidomide manufacturers are there in India?
India has 153 active thalidomide exporters with a combined export market of $1.9M across 822 shipments to 92 countries. The top 5 suppliers hold 65.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for thalidomide from India?
Average FOB unit price: $8.66 per unit, ranging from $0.10 to $206.67. Average shipment value: $2.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 153 verified Indian exporters of Thalidomide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 822 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 92 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
822 Verified Shipments
153 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists